Numinus will assess the clinical efficacy and safety of an extract generated using its proprietary technology in an upcoming Phase 1 clinical trial, which was announced in April 2021. Results revealed a highly efficient, scalable process that can be applied to other species of psychoactive fungi. Numinus initially tested the production process to rapidly generate a Psilocybe species extract as ‘proof of concept’. Sharan Sidhu, Numinus Bioscience General Manager and Science Officer The rapid production process announced today meets that goal by enhancing our ability to seamlessly formulate safe and effective products with consistent psychoactive properties at scale, with the regulatory confidence that comes with standardized products. The resulting psychedelic products are intended to be delivered in micro or macro dosages to help treat mental health disorders that affect millions of people around the world.Īt Numinus, one of the key goals of our lab’s research and discovery work is to support accessibility to psychedelic-assisted psychotherapies. The sustainable, reproducible and easily scalable process will be used to rapidly generate therapeutic products from psychoactive fungi species that contain psilocybin, other psychoactive compounds and a range of additional beneficial compounds, some of which Numinus researchers characterized for the first time in psychedelic fungi. (“Numinus Bioscience) has filed a provisional patent application with the United States Patent and Trademark Office ( USPTO) for a process that dramatically increases the production of therapeutics for use in psychedelic-assisted psychotherapy.
( CVE:NUMI ), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that its subsidiary Numinus Bioscience Inc. Process leads to standardized psychedelic extracts that are reproducible, scalable, cost-effective and commercially viable
0 kommentar(er)
